The machine-learning-based method identifies relationships between bacterial strains and tracks their movements in less time, using less memory than existing solutions.
The company has begun piloting the software, which is targeted towards bioinformatics companies and clinical laboratories, with early adopters ahead of the planned launch.
The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.
With the recent introduction of its Reveal platform, the company behind the 1000 Genomes Project browser wants to unlock the potential of the UK Biobank dataset.
After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
OMI researchers will apply and validate 1CellBio's inDrop system to generate predictive data for patients with undiagnosed immune dysfunction conditions.
